Your browser is no longer supported. Please, upgrade your browser.
Settings
SNY [NYSE]
Sanofi
Index- P/E27.47 EPS (ttm)1.80 Insider Own- Shs Outstand2.64B Perf Week-3.29%
Market Cap130.76B Forward P/E15.47 EPS next Y3.20 Insider Trans- Shs Float2.39B Perf Month2.38%
Income4.78B PEG4.86 EPS next Q- Inst Own9.60% Short Float0.05% Perf Quarter6.69%
Sales37.13B P/S3.52 EPS this Y18.90% Inst Trans3.54% Short Ratio0.57 Perf Half Y-11.25%
Book/sh22.73 P/B2.18 EPS next Y2.24% ROA4.60% Target Price55.00 Perf Year-1.98%
Cash/sh3.05 P/C16.23 EPS next 5Y5.65% ROE7.90% 52W Range43.57 - 57.42 Perf YTD8.40%
Dividend1.62 P/FCF- EPS past 5Y-3.90% ROI7.00% 52W High-13.03% Beta1.01
Dividend %3.28% Quick Ratio1.30 Sales past 5Y1.80% Gross Margin67.70% 52W Low14.62% ATR0.95
Employees113496 Current Ratio1.80 Sales Q/Q7.30% Oper. Margin19.20% RSI (14)55.32 Volatility1.54% 1.25%
OptionableYes Debt/Eq0.26 EPS Q/Q29.30% Profit Margin12.60% Rel Volume0.58 Prev Close49.44
ShortableYes LT Debt/Eq0.24 EarningsApr 30 BMO Payout48.30% Avg Volume2.21M Price49.94
Recom1.70 SMA202.09% SMA503.14% SMA200-0.62% Volume803,118 Change1.01%
Aug-03-12Downgrade Standpoint Research Buy → Hold
Jan-11-11Downgrade Jefferies Buy → Hold
Nov-16-09Initiated Deutsche Securities Buy
Oct-14-09Upgrade UBS Sell → Neutral
Aug-28-09Upgrade JP Morgan Neutral → Overweight
Jun-29-09Downgrade JP Morgan Overweight → Neutral
May-28-09Upgrade Citigroup Hold → Buy
Apr-30-09Upgrade JP Morgan Neutral → Overweight
Mar-23-09Upgrade Jefferies & Co Underperform → Hold
Mar-17-09Initiated Credit Suisse Outperform
Feb-19-09Upgrade JP Morgan Underweight → Neutral
Jan-26-09Initiated Jefferies & Co Underperform
Nov-07-08Downgrade UBS Neutral → Sell
Sep-23-08Downgrade Credit Suisse Neutral → Underperform
Oct-24-07Initiated Bernstein Mkt Perform
Sep-06-07Initiated UBS Neutral
Jul-18-07Upgrade HSBC Securities Neutral → Overweight
Jun-14-07Reiterated Banc of America Sec Buy $50 → $48
Jun-14-07Downgrade JP Morgan Overweight → Neutral
Jun-14-07Downgrade HSBC Securities Overweight → Neutral
Apr-01-15 12:31PM  What are examples of major companies in the drugs sector? at Investopedia
Mar-31-15 02:45PM  On the move: New hires and job transitions in the local life science industry at bizjournals.com
12:06PM  Pfizers Global Innovative Pharmaceutical Segment
Mar-30-15 06:06PM  What Products Affect Pfizers Revenue?
02:29PM  Nigerian Elections Extended Amid Glitches, Disruptions at MarketWatch
11:00AM  Genzymes Cerdelga® (eliglustat) Capsules Approved in Japan Business Wire
Mar-27-15 12:37PM  11 promising drugs poised to be the next billion-dollar blockbusters
12:00PM  Source to Close Europe ETF
Mar-26-15 06:40PM  Sanofi Reveals Cerdelga Data, FDA OK's Quadracel Vaccine - Analyst Blog
01:30PM  Genzyme Convenes Sixth Annual Gaucher Leadership Forum Business Wire
Mar-25-15 09:12PM  ENCORE Clinical Data Published in The Lancet Suggest Treatment with Oral Maintenance Therapy Effective in Previously Treated Gaucher Disease Patients Business Wire
12:15PM  Sanofi Pasteur Announces FDA Approval of Quadracel DTaP-IPV Vaccine for Children 4 through 6 Years of Age PR Newswire
Mar-24-15 04:51PM  Isis Pharmaceuticals Reports Phase I Data on Lipid Candidate - Analyst Blog
Mar-23-15 02:58PM  11 Promising New Drugs Expected to Make Billions in Sales at TheStreet
Mar-20-15 05:25PM  Amicus to Seek for Migalastat's Approval in the U.S., EU - Analyst Blog
04:38PM  Sanofi Inks Multi-Component Strategic Deal with Evotec - Analyst Blog
09:00AM  Goldman Downgrade Makes MannKind A Buy at Forbes
Mar-19-15 08:11PM  Evotec and Sanofi Sign Definitive Agreement for Major Multi-Component Strategic Alliance GlobeNewswire
03:01PM  Mark Levin to be honored with MassBio's annual Termeer award at bizjournals.com
11:03AM  Amicus Up As FDA, EU Green-light Quick Drug Filings at Investor's Business Daily
10:38AM  Novo Nordisk On Diversity In Diabetes Trials: "We Could Do Better" at Forbes
09:03AM  5 Breakout Stocks to Trade for Gains After the Fed's Bombshell at TheStreet
07:00AM  Sanofi Announces Top-Line Results for Cardiovascular Outcomes Study of Lyxumia® (lixisenatide) PR Newswire
02:11AM  Sanofi Announces Top-Line Results for Cardiovascular Outcomes Study of Lyxumia(r) (lixisenatide) GlobeNewswire
Mar-18-15 03:45PM  Investors Relieved? Akorn Stock Retakes 50-Day Line at Investor's Business Daily
01:00PM  To sell or not to sell: United Therapeutics faces choice with potential fast-track drug voucher at bizjournals.com
11:00AM  The Temptation of International Dividend ETFs ETF Trends
10:50AM  Regeneron Hits a 52-Week High on Positive Praluent Data - Analyst Blog
09:17AM  MannKind's Financial Health Complicated by Looming $100M Debt Payment at TheStreet
08:45AM  Nasacort® Allergy 24HR Partners with The Book of Awesome Author and Renowned Smell Expert to Celebrate the Happy Smells of Spring PR Newswire
Mar-17-15 11:39AM  Sanofi Upgraded On FX, Cholesterol Drug Promise at Investor's Business Daily
03:00AM  Form 20F for Sanofi at Company Spotlight
Mar-16-15 08:28PM  Top Stock Regeneron Breaks Out On Big Drug News at Investor's Business Daily
05:59PM  Regeneron/Sanofi's PCSK9 Drug Praluent Data Published - Analyst Blog
05:03PM  Amgen Presents Encouraging PCSK9 Inhibitor Repatha Data - Analyst Blog
03:17PM  Amgen, other drug company shares jump on cholesterol drug findings at MarketWatch
02:58PM  Alnylam Announces Positive Data from Natural History Study - Analyst Blog
08:00AM  Should You Be Worried About The Neurocognitive Side Effects Of The New Cholesterol Drugs? at Forbes
05:25AM  Five Things to Know Today: Snow record; NCAA brackets; Casino deadline; Sonic growth; Gene therapy at bizjournals.com
12:10AM  [$$] New Cholesterol-Lowering Drugs May Cut Heart-Attack Risk at The Wall Street Journal
Mar-15-15 05:47PM  New Cholesterol-Lowering Drugs May Cut Heart-Attack Risk at The Wall Street Journal
11:14AM  Sanofi, Regeneron: 18-Month Results of ODYSSEY LONG TERM Trial with Praluent(TM) (alirocumab) Published in The New England Journal of Medicine GlobeNewswire
11:00AM  Sanofi and Regeneron Announce 18-Month Results of ODYSSEY LONG TERM Trial with Praluent (alirocumab) Published in The New England Journal of Medicine PR Newswire
11:00AM  Regeneron and Sanofi Announce 18-Month Results of ODYSSEY LONG TERM Trial with Praluent (alirocumab) Published in The New England Journal of Medicine PR Newswire
11:00AM  New Cholesterol Drugs: Highly Effective But Important Questions Remain at Forbes
Mar-13-15 01:19PM  Watch these drug stocks Monday
11:52AM  Sanofi: Filing of the 2014 U.S. Form 20-F and French "Document de Référence" containing the Annual Financial Report at noodls
10:15AM  Patients With Advanced Prostate or Colorectal Cancer Face an Uncertainty in Their Future Treatment After NHS England Decision PR Newswire
Mar-12-15 06:11PM  Illumina Partners Merck KGaA to Develop Precision Medicine - Analyst Blog
05:06PM  Can weak production data intimidate European equity investors?
02:06PM  Weak Industrial Production Data Turkish Lira Continues Its Slide
09:20AM  SciClone (SCLN) Beats on Q4 Earnings, Gives 2015 Outlook - Analyst Blog
Mar-11-15 02:25PM  Activist investor at Ariad Pharmaceuticals has long history of wins at bizjournals.com
10:05AM  Monetary easing measures worked for Europe and Japan
Mar-09-15 08:01PM  Survey Shows That Oncologists Believe Cutting Drugs from Cancer Drugs Fund Won't Save NHS Money and Will Worsen Patient Outcomes PR Newswire
02:31AM  LAUNCH OF MIMABS, PRE-INDUSTRIAL DEMONSTRATOR ACCELERATING DEVELOPMENT OF IMMUNOTHERAPY ANTIBODIES Globe Newswire Europe
Mar-06-15 04:19PM  Biotech Bust? FDA Okays 1st Generic Biotech Drug at Barrons.com
04:44AM  Sanofi : ENGAGE Randomized Clinical Trial Evaluating Cerdelga® (eliglustat) for Treatment-Naïve Patients with Gaucher Disease Type 1 Published in The Journal of the American Medical Association at noodls
04:43AM  Sanofi : Sanofi and Lead Pharma to Develop Treatments for Autoimmune Diseases at noodls
04:42AM  Sanofi : Sanofi Appoints Olivier Brandicourt as Chief Executive Officer at noodls
04:41AM  Sanofi Receives FDA Approval of Once-Daily Basal Insulin Toujeo® at noodls
Mar-05-15 05:28PM  Top FDA Official Says Orexigen Study Result 'Unreliable,' 'Misleading' at Forbes
02:40PM  Kidney treatment developer Tricida raises $30M in Series B at bizjournals.com
02:05PM  On the move: Life science hires and job transitions at bizjournals.com
Mar-04-15 01:08PM  Regulators Want Drug Companies to Be Honest About FDA at TheStreet
Mar-03-15 11:44PM  Johnson & Johnson's Zytiga May Get a Boost at Barrons.com
01:55PM  Fighting dengue fever with genetically-modified mosquito ... CNBC
01:22PM  Goldman Downgrades MannKind To Sell, Should You Follow Their Lead? at Forbes
10:34AM  Why MannKind Could Lose Half Its Value at Barrons.com
08:30AM  NOTICE TO SANOFI EMPLOYEES: Zamansky LLC Investigates Sanofis U. S. Group Savings Plan For Possible ERISA Violations Business Wire
08:23AM  If You 'Want To Make A Good Drug Great' Cost Must Be Factored In at Forbes
08:16AM  MannKind Rating, Price Target Are Cut by Goldman on Slow Afrezza Launch at TheStreet
Mar-02-15 10:30AM  Looking for European Dividends? Say Oui to the France ETF ETF Trends
08:15AM  MannKind's Afrezza Earns Lackluster Review from Independent Drug Arbiter at TheStreet
Feb-27-15 04:05PM  What structural reforms are required by different countries? Market Realist
02:38PM  Merrimack Pharmaceuticals Q4 Loss Narrower Than Expected - Analyst Blog Zacks
12:10PM  Who Might Buy Puma Biotechnology? at Barrons.com
10:46AM  Oculus Innovative Sciences No One Trick Pony With Launch of New Animal Healthcare Division Company Spotlight
09:00AM  Afrezza's Initial Sales Create Buying Opportunity at Forbes
Feb-26-15 02:53PM  What You Should Know Before Watching Vice's Special About Curing Cancer at Forbes
10:15AM  MannKind: 'Encouraged By Early Feedback' on Afrezza Launch at Barrons.com
09:50AM  BioMarin's Q4 Loss Narrower than Expected, Gives 2015 View - Analyst Blog Zacks
Feb-25-15 10:18AM  MannKind: Nothing to See Here at Barrons.com
10:02AM  MannKind Reports Narrower Y/Y Loss in Q4, Afrezza in Focus - Analyst Blog Zacks
09:40AM  VIVUS Q4 Loss Wider than Expected, Qsymia Disappoints - Analyst Blog Zacks
Feb-23-15 11:06AM  Big pharma invests big money in research and development Market Realist
Feb-20-15 03:10PM  Lysosomal Therapeutics to use $20M to develop, test Parkinson's drug at American City Business Journals
09:00AM  Afrezza Will Succeed But Initial Sales Likely To Disappoint at Forbes
08:30AM  FDA Fast-Track Should Accrete Significant Value to This Overlooked Biotech Company Spotlight
08:06AM  Sales have been slower than expected. It takes time to educate the physician. Yahoo Finance Contributors
07:10AM  5 Tasks for Sanofi's New CEO at The Wall Street Journal
06:45AM  Genzyme's parent company names Bayer exec as its new CEO at American City Business Journals
Feb-19-15 04:56PM  Sanofi's new CEO CNBC
Feb-18-15 04:07PM  No, The New Cholesterol Drugs From Sanofi And Amgen Aren't Going To Cost $150 Billion A Year at Forbes
12:02PM  Regeneron Beats on Q4 Earnings Driven by Eylea Sales (revised) - Analyst Blog Zacks
07:10AM  Predictive analytics firm RapidMiner raises $15M; breaks into Internet of Things market at American City Business Journals
Feb-17-15 04:59PM  CVS girds for battle over cholesterol drugs at MarketWatch
11:31AM  ENGAGE Randomized Clinical Trial Evaluating Cerdelga® (eliglustat) for Treatment-Naïve Patients with Gaucher Disease Type 1 Published in The Journal of the American Medical Association Business Wire
Feb-12-15 05:37PM  Stock Therapy: Hedge funds target biotech CNBC
04:15PM  Genzyme Presents Data from its Phase 1b Program for Niemann-Pick Type B at the Lysosomal Disease Networks WORLD Symposium 2015 Business Wire
Sanofi researches, develops, and markets various therapeutic solutions. Its products comprise diabetes solutions, including Lantus, Apidra, and Insuman that are human insulin analogs; Amaryl, an oral sulfonylurea; Lyxumia, a glucagon-like peptide-1 receptor agonist; and Afrezza, an inhaled insulin to improve glycemic control, as well as Toujeo, an insulin glargine. The company also offers Cerezyme to treat gaucher disease; Myozyme/Lumizyme for the pompe disease treatment; Fabrazyme for fabry disease treatment; and Aldurazyme to treat mucopolysaccharidosis type I, as well as provides Aubagio and Lemtrada for multiple sclerosis. In addition, it provides Jevtana for prostate cancer; Taxotere for the treatment of breast, non-small cell lung, prostate, gastric, and head and neck cancers; Thymoglobulin to treat acute rejection in organ transplantation, aplastic anemia, and graft-versus-host diseases; Eloxatin for colorectal cancer; Mozobil for treating hematologic malignancies; and Zaltrap for oxaliplatin resistant metastatic colorectal cancer. Further, the company offers other prescription drugs, such as Plavix for atherothrombosis and acute coronary syndrome; Lovenox for the treatment and prevention of deep vein thrombosis and acute coronary syndromes; Aprovel/CoAprovel for hypertension; Renagel/Renvela to treat chronic kidney disease; Depakine for epilepsy; Synvisc/Synvisc-One for the treatment of pain associated with osteoarthritis of the knee; Stilnox/Ambien/Myslee to treat sleep disorders; Multaq for atrial fibrillation; Allegra for the treatment of allergic rhinitis and urticarial; Actonel for osteoporosis and paget's disease; and Auvi-Q/Allerject for the treatment of severe allergic reactions. Additionally, it offers consumer health care products and generic medicines; and vaccine and animal health products. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sanofi10% OwnerDec 24Buy398.7930,00211,964,50122,859,144Dec 29 05:40 PM
Sanofi10% OwnerDec 23Buy392.23171,45767,251,14222,829,142Dec 29 05:40 PM
Sanofi10% OwnerOct 16Buy335.35122,12740,955,05722,657,685Oct 20 05:45 PM
Sanofi10% OwnerOct 15Buy328.16158,36851,970,26522,535,558Oct 17 05:05 PM
Sanofi10% OwnerJul 15Buy314.92129,10040,656,17622,204,841Jul 17 05:50 PM
Sanofi10% OwnerJul 14Buy318.18150,00047,726,79722,075,741Jul 15 05:45 PM
Sanofi10% OwnerJul 11Buy315.41150,00047,311,83621,925,741Jul 15 05:45 PM
Sanofi10% OwnerJul 10Buy311.08175,00054,439,07321,775,741Jul 14 05:46 PM
Sanofi10% OwnerJul 09Buy308.27195,00060,112,31121,600,741Jul 10 05:45 PM
Sanofi10% OwnerJul 08Buy311.67153,00047,685,74321,405,741Jul 10 05:45 PM
Sanofi10% OwnerJul 07Buy312.90256,70080,320,79521,252,741Jul 08 05:42 PM
Sanofi10% OwnerJul 03Buy311.02100,00031,101,94620,996,041Jul 08 05:42 PM
Sanofi10% OwnerJul 02Buy307.25212,40065,259,55220,896,041Jul 03 06:00 PM
Sanofi10% OwnerJul 01Buy300.20212,40063,761,42120,683,641Jul 03 05:46 PM
Sanofi10% OwnerJun 30Buy282.54212,40060,010,47920,471,241Jul 01 05:39 PM
Sanofi10% OwnerJun 27Buy275.3850,00013,769,09220,258,841Jul 01 05:39 PM
Sanofi10% OwnerMay 19Buy300.04190,75157,233,71620,208,841May 21 05:02 PM